鲁南制药：多项单品全球产销第一

Core Viewpoint - The article highlights the significant achievements and innovations of Lunan Pharmaceutical, emphasizing its commitment to quality and technological advancement in the pharmaceutical industry, positioning it as a leading brand in Shandong and beyond [1][2][5]. Group 1: Company Achievements - Lunan Pharmaceutical has achieved a production capacity of 1,500 tons of clavulanate potassium annually, accounting for nearly one-third of global demand, making it the world's largest producer [2]. - The company has invested over 10 billion yuan in research and development over the past decade, resulting in numerous successful products and innovations [4]. - Lunan Pharmaceutical ranked 13th in the "2025 China Pharmaceutical R&D Comprehensive Strength Ranking" and has established multiple national and provincial-level innovation platforms [5]. Group 2: Product Development and Innovation - The company has seen a surge in new product launches, with an expected 40 to 50 products entering production this year, particularly in the innovative drug sector [5]. - Lunan Pharmaceutical's first antibody-based biopharmaceutical, Yilidali Rituximab Injection, was approved after 15 years of development, marking a significant milestone in its product portfolio [6][8]. - The company has optimized production processes, saving approximately 4 million yuan annually through continuous research breakthroughs [2]. Group 3: International Expansion - Lunan Pharmaceutical's international business has grown tenfold from 200 million yuan in 2014 to 2 billion yuan in 2024, with 72 formulation products approved in 129 countries and regions [10][12]. - The company has transitioned from exporting raw materials to exporting formulations, increasing profit margins by 5 to 7 times [11]. - Lunan Pharmaceutical has established partnerships with over 200 global companies and is actively expanding its presence in emerging markets across Asia, Africa, and Eastern Europe [12].